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This  is  the  first  description  of the  physiological  mode  of recruitment of 
precursor  properdin  (pre-P) 1 and  of the  physiological  role  of the  recruited 
protein. It has now been established that properdin does not participate in the 
initiation of the properdin pathway (1). It has also been demonstrated that the 
properdin pathway can operate in absence ofproperdin, although with a reduced 
efficacy (1).  These observations  do not  support  the  interpretation  of earlier 
studies  (2,  3), which were performed with activated properdin  (P),  an altered 
form of the protein, which does not occur in fresh normal serum. Using P, it was 
possible to generate a fluid phase C3 convertase in whole human serum (2, 4) 
and to stabilize the cell-bound C3/C5 convertases, which are exceedingly labile 
enzymes  (5,  6).  It  was  therefore  assumed  that  the  activation  of properdin 
precedes the formation of  the enzymes. In fact, properdin has been invoked as an 
essential component for the initiation of the pathway (7). 
In this paper we wish to report that unaltered properdin, as it occurs in fresh 
serum and as it may be isolated under specified conditions,  2 enters the pathway 
as the final component. It is activated and bound by the solid phase complex of 
C3b  and  proactivator  (Factor B).  The net effect of properdin recruitment is 
entirely confined to  the  preservation of the  existing enzymes by  conferring 
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physical stability  upon them and by protecting  them against the destructive 
action  of  the C3b inactivator. 
Materials and Methods 
Purified Components.  Highly purified human C3 (8), proactivator (Factor B) (9), proactivator 
convertase (Factor D) (10), P (2), C5 (8), C6 (11), and C7 (11) were isolated as described elsewhere. 
The components were trace labeled with '25I by the chloramine-T method  (12).  C3b inactivator 
(C3bINA) was purchased from the Cordis Corp., Miami, Fla. 
Diluents and Reagents.  The following isotonic Veronal-NaC1 buffers were used  (13): VB  ++, 
sodium Veronal-buffered saline, pH 7.3,  containing 0.15  ×  10  -3 M CaC12 and 1 ×  10 -3 M MgC12; 
GVB  ++, VB ÷+ containing 0.1% gelatin; GVBE, GVB without Ca  ++ and Mg  ++ containing 0.01 M 
EDTA. VB  ++ of half physiological ionic strength  (0.075)  consisted of 1 vol VB ++ and  1 vol 10% 
sucrose in  water containing 1 × i0  -3  M  MgCls. 
C5-9  reagent  consisted  of  guinea  pig  serum treated  with 1  M  KCNS  at  4°C overnight and 0.015 
M  hydrazine  at  37°C for  45  rain.  The  dialyzed  reagent  is  reconstituted  with  isolated  human C5. 
Partial  Purification  of  pre.P,  pre-P was partially  purified  from normal human serum by 
sequential  TEAE and  CM Sephadex  chromatography. Normal  human serum  dialyzed  against  0.02 
M  sodium phosphate buffer,  pH 7.3,  was applied to a TEAE  column equilibrated  with the same 
buffer.  The  first  protein  fraction  which  emerged  from  the  column  contained pre-P  and  was  dialyzed 
against 0.02  M  sodium phosphate buffer,  pH 6.0,  and applied to a CM  Sephadex column equili- 
brated with  the  same  buffer.  The  column  was  washed  with  starting  buffer  adjusted  to  16  mmho/cm 
with NaCl. The pre-P  was then eluted  with starting  buffer  adjusted  to 32 mmho/cm with NaCI. 
Although  this  preparation  ofpre-P  still  contained other  proteins,  the  protein  was  completely in  the 
precursor form and was found  to behave functionally  as highly purified  pre-P.  2 
Preparation  of  EAC4b,3b.  This intermediate complex was prepared by incubating EACI,4b 
with  nonoxidized C2  for  3  rain  at  30°C (14).  The  resulting  EAC1,4b,2a  cells  were  then  converted to 
EAC4b,3b by  treatment  of  10  ~  cells  with  95 ~g  C3  for  15  min  at  37°C and subsequent  incubation for 
120  min at  37°C in  0.01  M EDTA to  remove C1 and  C2a. These  conditions  produced  cells  containing 
from 15,000  to  30,000  C3b  molecules  per  cell.  In  certain  experiments  the  amount  of  C3  was  varied  to 
produce  cells  with  less  than  1,000  to  over  60,000  C3b  molecules  per  cell.  The  C3b  molecules on  these 
cells  are focally  distributed  as was shown by electron  microscopy (15). 
Preparation  ofEC3b(try).  Nonsensitized sheep erythrocytes  were suspended at a concentra- 
tion  of  I x 109  cells/ml.  1-ml aliquots  of  this  cell  suspension  were centrifuged  and the supernate 
decanted. From 0.1  to  7  mg of  purified  C3 was added  to  the  cell  pellets  in  a final  vol  of  i  ml VB  ++. 
To each  tube,  trypsin  (Worthington Biochemical  Corp.,  Freehold, N. J.)  was added to achieve an 
enzyme to C3 ratio  of  1:100  (weight per weight) and incubated at room temperature for  3 min. 
Thereafter,  a 10-fold  excess  of  seybean  trypsin  inhibitor  over  trypsin  was  added, and  the  cells  were 
washed with buffer  three times. The resulting  complex, EC3b(try), contained from 500 to 33,000 
C3b molecules per  cell  which were presumed to  be randomly distributed  over the cell  surface. 
Assay ofpre-P.  The reaction mixture contained 0.5 /~g Factor B, 5 ng Factor D, 1 x  107 
EAC4b,3b, and an appropriate amount of  pre-P in a total  vol  of  50/~I  GVB ++. This mixture was 
incubated at 37°C for 5 rain.  The reaction was stopped by the addition  of EDTA  to a final 
concentration  of  0.01  M, and  the  labile  convertase  was  decayed  by  further  incubation  for  10  min at 
37°C.  The pre-P-stabilized  convertase was  measured by  the  extent  of  hemolysis  observed after  the 
addition  of  I  ml of  1:50  diluted  guinea  pig  sertun  (GPS)  in  0.04  M  EDTA and incubation for  30  rain 
at 37°C. 
Assay of  P.  Samples containing P were incubated with 1 x 107  EAC4b,3b for  10  rain  at  37°C. 
The cells  were then washed with GVB ++ two times and the pellets  resuspended in 50 ~l GVB ++ 
containing the same amounts of Factors B  and D  as in the pre-P assay,  and the stabilized 
convertase was measured as above. The ratio  of P to total  properdin activity  represents the 
fractional  content of  15  in a given  properdin preparation.  This ratio  was generally at  least  0.8  for 
preparations of  P and no higher  than 0.05  for  preparations of  pre-P. 
Intermediate Complexes  and Activity Assays Used for the Demonstration of the C3bINA Ef- 
fect.  The intermediate complex EC~  was prepared by incubating 1 x  107 EC3b containing 
22,000 C3b molecules per cell with 1 ~g of Factor B, 20 ng of Factor D, and 200 ng ofpre-P in a total 1078  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
vol of 50 ~1 for 10 min at 37°C. EC3b,P was prepared by incubating another aliquot of EC3b with 
200 ng of P  for 10 rain at 37°C in a  total vol of 100  /~1 GVB  ÷+. EC3b,B was prepared with the 
identical procedure,  except that buffer instead of properdin was added.  All intermediates were 
incubated in a final vol of 200 #al with 50 U  of C3bINA for 5 min at 20°C. 
The residual activity of the EC3b,~ and EC3b was determined by washing the C3bINA-treated 
cells with GVB  +÷ and assembling the stabilized C5 convertase as above with Factors B, D and B, 
D, and P, respectively. The activity remaining was measured by the addition of GPS-EDTA 1:50 
for 20 min at 37°C (after 10-min decay of the labile enzyme) and compared with controls that were 
not treated with C3bINA. 
The residual activity of EC3b,P,B was determined after washing the C3bINA-treated cells by 
the  addition  of GPS-EDTA  1:50  and  incubation  for 20  rain  at  37°C.  The  same  procedure  was 
followed for EC3b.-~,B, except that C5-9 reagent was used for lysis instead of diluted GPS-EDTA. 
The residual activity of the labile convertases was measured in the same way except that the 
washing and decay steps were omitted. Either C5-9 reagent or GPS-EDTA 1:50 were added directly 
after incubation with C3bINA for 5 min at 20°C. Lysis was allowed to develop for 20 min at 37°C. 
Results 
Activation of Properdin Precursor.  The most important question asked in 
this investigation was: how is properdin activated? Although properdin occurs 
in serum as a precursor, it is usually isolated in an altered form. Because the 
isolated protein is capable of forming a soluble C3 convertase with Factors B, D, 
and C3,  it has been termed activated properdin or P  (2,  4).  Under specified 
conditions,  2  properdin may be isolated in precursor form. This form behaves like 
properdin in untreated, normal serum. Added to properdin-depleted serum, it 
causes no C3 consumption. But it participates in the alternative pathway after 
its initiation by particulate activators. 
To investigate the mode of properdin recruitment, pre-P was labeled with 125I 
and offered at physiological ionic strength to C3b-bearing erythrocytes. Unless 
stated otherwise, these cells are EAC4b,3b cells which will be referred to in the 
following simply as EC3b.  As seen in Fig.  1, no uptake of 125I pre-P occurred, 
although 12~I P was bound in a dose-related fashion. In contrast, uptake of pre-P 
was observed reproducibly under conditions that allowed formation of the labile 
C3/C5 convertase (Fig. 2). Uptake was dependent on the simultaneous presence 
of Factors B, D, and Mg, or on the prior formation of the enzyme to which pre-P 
binding occurred even in the presence of EDTA. Uptake required a concentra- 
tion of pre-P approaching that in normal serum to saturate all pre-P binding- 
activation sites. In spite of the high pre-P concentration, uptake did not exceed 
0.5% of input with the number of cells employed. Repeated exposure of the 
supernate to aliquots of fresh EC3b,B resulted in identical pre-P uptake, show- 
ing that all of the pre-P was potentially capable of undergoing activation. There 
was no detectable activation or inactivation of pre-P in the fluid phase. The loss 
of pre-P  activity in  the  fluid phase was fully accounted for by the  cellular 
uptake.  Thus,  evidence for turnover of pre-P by EC3b,B  was not obtained. 
Although the activating principle constitutes an enzyme, activation of pre-P 
does not appear to be due to an enzymatic reaction. Evidence for the physical 
nature of the transition of pre-P to P will be presented.  2 
The Functional Manifestations of  Binding-Activation of  pre-P.  The effect of 
pre-P binding on the cell-bound C~  enzyme is illustrated in Fig.  3.  After 
addition ofpre-P, the cells were held at 37°C in 0.01 M EDTA for 10 min to effect 
decay of the labile C3b,B complex. Subsequent exposure to C3-9 led to lysis of R.  G.  MEDICUS~  O.  GOTZE~  AND  H.  J.  MULLER-EBERHARD 
22,000 
1079 
1~oo 
14,000 
-  ~o,  ooo 
6000 
2000  PrecDrspr Properdill 
loo  2oo  3oo  400  s~c 
1251-p or P  (ngJ 
Fza.  1.  Binding of P but not of pre-P to EC3b at physiological ionic strength. To 1 x  107 
EC3b containing 27,000 C3b molecules per cell, either 'zsI-i) or '~SI-pre-P were added in a 
total  vol  of  100  /~l.  After  10  min  at  37°C,  the  cells  were  washed  and  the  uptake  of 
radioactivity was determined. The specific radioactivity was 6.4 x  10  z cpm/~g for P and 1.1 
x  l0  b cpm//zg for pre-P. 
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FIG.  2.  The mode of recruitment ofpre-P at physiological ionic strength. To 1 x  l0  T  EC3b 
containing 15,700 C3b molecules per cell was added 2/zg of Factor B and 30 ng of Factor D 
and precursor properdin in a final vol of 130 ~1. After 10 min at 37°C, the cells were washed 
and the uptake of radioactivity determined. 
the  cells,  indicating that  a  proportion  of the  enzyme complexes had  been 
protected by pre-P against rapid decay. Therefore the effect of pre-P on the 
enzyme is the same as that of P  (5, 6). 
The results show that binding-activation ofpre-P is accomplished by the cell- 
bound complex of C3b and activated Factor B.  Stoichiometric measurements 
using radiolabeled C3 and pre-P indicated that at satiJration of all pre-P binding 
sites, one molecule of pre-P was bound per 30-50 molecules of cell-bound C3b. 
The results of five different experiments are listed in Table I.  They may be 
interpreted to indicate that a multiplicity of  bound C3b molecules is required for 
the pre-P-activating complex. 
The C3 and C5 Convertase Function of the Labile and the pre-P-Stabilized 
Enzyme.  In the following it will be shown that the cell-bound complex of C3b 
and activated Factor B can enzymatically  act on C3 and on C5. Fig. 4 shows C3 
uptake and overall consumption by the cell-bound, pre-P-stabilized enzyme. C3 1080  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
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FIG.  3.  Stabilization of the labile EC3--~,B complex by binding-activation ofpre-P. To 1.4 × 
107 EC3b containing 7,000 C3b molecules per cell was added pre-P, 0.5 ~g of Factor B, and 40 
ng of Factor D in a final vol of 44 ~1. After 10 rain at 37°C,  100 ~1 of GVBE was added and the 
cells were washed and decayed for 10 min at 37°C  in GVBE. Control: EC3b plus pre-P,  10 
rain at 37°C, washed in GVB  ++, Factors B and D added in amounts indicated above, decayed 
10 rain at 37°C in GVBE. Lysis was initiated in both sets of cells by addition of GPS-EDTA 
1:50 and developed for 20 rain at 37°C. 
TABLE I 
Properdin/C3b Ratio at Saturation of all Binding-Activation 
Sites for Precursor Properdin on EC3b 
C3b molecules bound  pre-P molecules  Molecules C3b 
per cell  bound per cell  Molecules pre-P 
10,700  200  54 
15,700  476  33 
26,800  783  34 
27,000  900  30 
27,200  610  45 
To 5  ×  107 EC3b, containing the indicated number of C3b molecules per 
cell, was added 5  t~g of Factor B, 200 ng of Factor D, and 1 tLg of ]25I- 
labeled pre-P in a  total vol of 250 ~1 GVB  ÷+. After 10 min at 37°C,  the 
cells were washed and the uptake of radioactivity determined. The sp 
act of the '2~I pre-P was 1.1 ×  10  ~ cpm/ttg. The number of C3b molecules 
per cell was determined using C3 with low specific radioactivity. 
uptake approached 23% of total consumption. The apparent turnover of C3 was 
35 molecules per single C3b,P,B site per  15 min at 37°C. 
Fig. 5 shows the ability of C3b,P,B to act directly on C5 without requiring a 
supply of native C3. In this experiment, which is representative of more than 10, 
highly purified C5,  C6,  and C7 were reacted with cells bearing the stabilized 
enzyme  and  the  formation  of C5b,6,7  sites  was measured  subsequently.  The 
turnover of C5, although hemolytically effective, was exceedingly slow. Uptake 
of C5 did not exceed one to two molecules per single pre-P-stabilized  enzyme 
site per 15 min at 37°C.  Consumption of C5 in the fluid phase was not measur- 
able. 
It should be stressed that the unstabilized enzyme also is capable of acting on 
C5 and of initiating cell lysis in the absence of C3. The C5 convertase function of 
the labile enzyme can be demonstrated only under conditions allowing regenera- 
tion of the enzyme, that is, in presence of excess Factors B and D. R.  G.  MEDICUS,  O.  GOTZE,  AND  H.  J.  MULLERoEBERHARD  1081 
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FIG.  4.  The  C3  convertase function of the pre-P-stabilized enzyme.  To  1.4  ×  l0  s EC3b 
containing 10,700 C3b molecules per cell was added 2.5 #ag of Factor B, 150 ng of Factor D, 
and 4  ~g of pre-P in a  total vol of 100/~1. After 10 min at 37°C,  the cells were washed in 
GVBE, the labile enzyme was decayed for 10 min at 37°C,  and 1~5I-C3 was added in amounts 
from 0 to 10 ~g in a final vol of 100/~l. After 15 rain at 37°C,  the cells were centrifuged, and 
C3 was measured by hemolytic assay and on the cells by radioactivity measurement. 
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FIO.  5.  The C5 convertase function of the pre-P-stabilized enzyme and the lack of native 
C3 requirement. To 1 x 107 EC3b containing 10,500 C3b molecules per cell was added 0.5 pg 
of Factor B, 20 ng of Factor D, and 150 ng of P. After 10 min at 37°C, the cells were washed 
and suspended in 60/~l GVB  ++ containing C5 and 0.1 ~g each of C6 and C7. After 10 rain at 
37°C,  1 ml of GPS-EDTA  1:500  was added as a  source of C8,9,  and lysis was allowed to 
develop for 30 rain at 37°C. 
Assembly of the Stabilized C3/C5 Convertase as a Function of Number and 
Distribution  of Cell-Bound C3b Molecules.  Does the C5 convertase differ in 
composition from the  C3  convertase,  specifically in  C3b  content? Since the 
alternative C5 convertase so far could only be generated on a surface and not in 
free solution,  cells were prepared bearing C3b  in two distinct distributions. 
EAC4b,3b cells exhibit on their surface circumscribed clusters of bound C3b 
molecules (14). In contrast, EC3b(try) cells, prepared by treating E with C3 and 
trypsin, are likely to contain a random distribution of C3b molecules on their 
surface, because attachment to the cells occurred from the fluid phase and not 
through the membrane bound C3 convertase. 125I-labeled C3 was used for the 
preparation of these complexes in order to be able to enumerate the bound C3b 1082  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
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FIG.  6.  Dependence of pre-P-stabilized C5 convertase on number and distribution of cell- 
bound C3b molecules. To I  x  l0  T  EAC4b,3b or EC3b(try) was added 4.2 ~g of  Factor B, 20 ng 
of Factor D, and 100 ng ofpre-P in a total vol of 30 ~tl. After 10 min at 37°C, 20 ~l of GVBE 
was added, and the labile enzyme was decayed for 10 min at 37°C. Either 200 ~1 of C3-9 or 
200 pl of C5-9 were added, and lysis was determined after 30 min at 37°C. 
molecules. The two distinct cell preparations were then subjected to the assem- 
bly  of pre-P-stabilized  C3/C5 convertase with  the  precursor proteins  of the 
enzyme present in excess. As is demonstrated in Fig. 6, EAC4b,3b  allowed the 
formation of the enzyme at low numbers of C3b molecules per cell,  EC3b(try) 
only at high numbers of C3b molecules per cell.  Treating the cells with C3-9, 
which allows to assay for C3 convertase activity, both types of cells underwent 
lysis, although at different C3b multiplicities per cell.  Treating the cells with 
C5-9, Which allows to assay for C5 convertase activity, EAC4b,3b  was strongly 
positive, whereas EC3b(try) was not. This shows that pre-P-stabilized C5 con- 
vertase can be formed on C3b-bearing cells without further C3 provided C3b is 
focally distributed on the cell surface. These results lend support to the concept 
that generation of C5  convertase, unlike that of C3  convertase, necessitates 
multiple C3b molecules in close proximity. They further show that these mole- 
cules may be firmly bound to the cell surface before assembly of the C5 conver- 
tase. 
Functional Comparison of  pre-P and P.  The functional difference between 
pre-P and P has been pointed out in Fig.  1 which shows that at physiological 
ionic strength P can bind to EC3b and pre-P cannot. That pre-P does recognize 
C3b may be demonstrated at half physiological ionic strength. As shown in 
Table H, binding under these conditions is specific and reversible by elevating 
the ionic strength to 0.15. The loose complex between EC3b and pre-P can be 
converted to the cell-bound stabilized C5 convertase upon addition of Factors B 
and D. That after binding-activation pre-P continues to differ in function from P R.  G.  MEDICUS,  O.  C~TZE,  AND  H.  J.  MT)LLER-EBERHARD 
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Reversible Interaction  of Precursor Properdin  with Cell Bound C3b 
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Treatment of 125I-pre-P 
Initial ionic strength 
0.15  0.075 
EC3b 
Uptake (cpm)  378  10,700 
C5 Convertase (z)*  0.03  0.91 
Elution ofpre-P at/~ =  0.15 
Supernatant  (cpm)  -  8,800 
Pellet (cpm)  -  1,040 
EA 
Uptake (cpm)  389  1,966 
* Measured after addition of Factor B, D, and Mg to cell pellet. 
Buffers contained 0.5 mM MgCI~. EC3b and EA: 5 x  107 cells. Total reaction vol: 200 
~l. Reaction time: 10 min, 37°C. 
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Fzo.  7.  Uptake  of P  by EC3b without apparent  saturation.  To  1.5  x  107 EAC4b,3b in 
GVB  +÷ containing 5,500 C3b molecules per cell was added radiolabeled P in a total vol of 200 
~l. After incubation for 10 min at 37°C, the cells were washed, and the radioactive uptake 
was determined. Uptake did not exceed 1% of input. At the highest input the concentration 
ofproperdin is 3½ times that in serum. Control experiments were performed using EAC4b. 
is apparent from uptake measurements. Fig. 7 illustrates an apparently unlim- 
ited capacity of P to bind to EC3b. As many as 10 molecules of P may bind to 1 
molecule of C3b  on the surface of EC3b.  This  is  in striking contrast to  the 
behavior of activated pre-P. Uptake of pre-P which only occurs in presence of 
Factors B and D yields initially a linear dose response curve and then becomes 
independent of input,  indicating saturation of all  binding sites  (Fig.  2).  At 
saturation the molar ratio of bound pre-P to bound C3b  is  1 to 30-50. Fig.  8 
indicate~  that the half-life of pre-P-stabilized C3/C5 convertase is 5 min at 37°C 
compared to 1.5 min of the unstabilized enzyme. This stabilization is independ- 
ent of the number of pre-P molecules bound to the cells. When P is offered to 
EC3b under identical conditions, namely simultaneous with Factors B and D, 
the degree of stabilization observed is identical to that effected by pre-P.  In 
contrast, when P  is offered before the addition of Factors B and D,  variable 
degrees of stabilization  are found.  The variability is  dose dependent and is 
undoubtedly related to the uptake of P which, as shown in Fig. 7, is proportional 
to input. 1084  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
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FIG.  8.  Comparable enzyme stabilization by pre-P and P  and increased stabilization by 
upon reverse assembly of the enzyme. To 1 ×  108 EC3b containing 30,000 C3b molecules per 
cell was added 3 ~g of Factor B, 200 ng of Factor D, and 400 ng ofl  ~ (EC3b + P,B,D) or 400 ng 
of pre-P (EC3b +  pre-P,B,D) in a final vol of 275 ~1. After 10 min at 37°C, 200/~l GVBE was 
added,  and the unstabilized enzyme was decayed for 10 min at 37°C.  40-/~1 samples were 
then withdrawn at 4-rain intervals and added to 1 ml GPS-EDTA 1:100.  Lysis was quanti- 
tated after 20 min at 37°C. Reverse assembly (EC3b,P +  B,D) was performed under identical 
conditions, except that P was offered during a 10-min preincubation period. For comparison, 
the decay of the unstabilized enzyme is shown (EC3b +  B,D). 
Three  Modes  of Regulation  of  the  C3/C5  Convertase and  of Its  Sub- 
units.  The first mode of control is represented by the intrinsic decay of  the C3/ 
C5 convertase which is modified by pre-P as well as by P, as described above. 
The second mode of  control is effected  by the serum enzyme  C3bINA. It acts on 
at least five different entities, which contain C3b and which are inactivated by 
the action of  the enzyme on C3b. The relative susceptibility of  the five complexes 
containing C3b and of C3b alone is indicated in Table III. The most susceptible 
entity is C3b per se, and the least susceptible is the complex C3b,P,B.  Properdin 
and Factor B exercise a  protective function against C3bINA which properdin 
alone continues to provide to some extent after dissociation of Factor B. When 
the C3bINA succeeds in acting on the residual C3b,P  complex, properdin is 
released into the fluid phase as was demonstrated using l~sI-P (Fig. 9). 
The third mode of control involves the disassembly of the properdin-stabilized 
convertase by the accelerator of C3bINA (30). In experiments not shown here, it 
was found that the accelerator dissociates only Factor B from the complex while 
remains bound to  C3b. After washing of the accelerator-treated cells, the 
stabilized enzyme activity could be fully recovered upon addition of Factors B 
and D. 
Reverse Assembly of the Stabilized C3/C5 Convertase.  Reverse assembly of 
the properdin-stabilized enzyme begins with the complex EC3b,P which results 
from decay or active disassembly of the pre-P-stabilized form of the enzyme. 
Alternatively, it may begin with the binding of soluble P to EC3b.  Addition of 
Factor B to EC3b,P leads to the Mg-dependent formation of  EC3b,P,B in absence R.  G.  MEDICUS,  O.  GOTZE,  AND  H.  J.  MULLER-EBERHARD 
TABLE  III 
Susceptibility of Bound C3b and Various C3b Containing 
Complexes to Inactivation  by C3b Inactivator 
Intermediate complex 
Activity remaining after 
treatment with C3bINA 
(5 min, 20°C) 
% 
EC3b,P,B  100 
EC3b,P  90 
EC3b,B  60 
EC3b~,B  40 
EC3b.,P,B  30 
EC3b  5 
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FIG.  9.  Release of radioactive properdin upon destruction of EC3,P by C3bINA. The left 
panel shows the loss of hemolytic reactivity of EC3b,P and the right panel the release of'2~I- 
properdin from the same cells during treatment with C3bINA. To 5 x  107 EC3b containing 
34,700  C3b molecules per cell was added 5 ~g of ~2~I P in a final vol of 100 ~l. After 10 min at 
37°C,  the EC3b,P was washed and exposed to C3bINA or buffer (control) at 37°C in a total 
vol of 110 ~1. At intervals, 10-~l aliquots were removed and the cells washed and suspended 
in 100 ~tl GVB  ÷+ containing 1 ~g of Factor B and 20 ng of Factor D. After 10 min at 37°C, 100 
~l of GVBE was added and the labile enzyme decayed for 10 min at 37°C. 1 ml of GPS-EDTA 
1:50  was  added  and  lysis determined  after 20  min  at 37°C.  Residual  P  was detected by 
measuring the cell-asseciated radioactivity. 
of Factor  D.  This  complex exhibits  no  measurable enzymatic activity.  On 
addition of Factor D, enzyme activity appears, and the uptake of Factor B is 
reduced by 30% (Fig. 10). The reduction in cell-bound radioactivity corresponds 
numerically to the relative size of the activation fragment (Ba)  of Factor B, 
which is released from the complex (10). A low degree of Factor B binding was 
also observed with EC3b in absence of P. The Mg-dependent complexes of Factor 
B, EC3b,B and EC3b,P,B were dissociated by EDTA. The appearance of C3/C5 
convertase activity upon reverse assembly of  the enzyme is shown in Fig. 11 as a 
function of P input. 
Discussion 
In this  study we addressed ourselves to  these questions:  (a)  What  is  the 
physiological mechanism of properdin activation? (b)  What is the function of 1086  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
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FIG.  10.  Magnesium-dependent binding of nonactivated Factor B  to  cell-bound C3b or 
C3b,P sites. To 1.4 ×  107 EC3b containing 27,000 C3b molecules per cell was added 750 ng of 
1  ~. After 10 rain at 37°C,  the cells were washed in GVB  ++ and suspended in 64 ~l GVB *+ 
containing Factor B and, when indicated, 30 ng of Factor D. Aider 10 min at 37°C,  the cells 
were washed either in GVB  ++ or GVBE, and the radioactivity was measured. The uptake of 
Factor B on EC3b cells was performed the same way. The sp act of the 125I-labeled  Factor B 
was 150,000 cpm//xg. 
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FIG.  11.  Reverse assembly of the P-stabilized C5 convertase on EC3b. To 8 × 106 EC3b(try) 
containing 13,800 C3b molecules per cell was offered P,  470 ng of Factor B, and 60 ng of 
Factor D Jn a total vol of 27/~l. Ai~r 16 rain at 37°C,  I ml of GPS-EDTA 1:10 was added and 
lysis was allowed to develop for 20 rain at 37°C. 
activated pre-P under physiological conditions? (c) What is the composition of 
the multisubunit C3 and C5 convertases of which properdin appears to become a 
part?; and (d) How are these enzymes controlled? 
At the beginning of this study we considered the possibility that particle- 
bound C3b  might serve as the properdin-activating principle by imposing a 
conformational change on pre-P. Bound C3b had previously been recognized as R.  G.  MEDICUS,  O.  GOTZE,  AND  H.  J.  MULLER-EBERHARD  1087 
the receptor  for  P (4).  In contradistinction  to P, pre-P was found to be entirely 
incapable of  interacting  with bound C3b at physiological  ionic  strength,  except 
in presence of Factors B, D, and Mg  (Fig. 1, 2). Those, of course, are the 
conditions  of  formation of  the labile  C3/C5 convertase.  Since pre-P was found to 
be bound by the assembled, cell-bound  enzyme even in presence of  EDTA, the 
complex of  C3b and activated  Factor B could be identified  as the binding and 
activating  principle  of  pre-P. 
Immediately the question arose  as to  whether the binding-activation  of  pre-P 
is an enzymatic reaction.  This possibility  seemed remote, because the enzyme 
specificity  of  the complex is  known to  be directed  toward C3 and C5. Neverthe- 
less,  the claim of  an enzymatic activation  of  pre-P had been reported (16).  Such 
a mechanism has virtually  been excluded by the following  findings:  (a)  there is 
no  detectable  turnover of  pre-P;  (b)  one  enzyme site  causes  binding  of  maximally 
one molecule of  pre-P, as exploratory experiments with radiolabeled  Factor B 
and pre-P indicate;  3 and (c) no difference  in molecular size  can be detected 
between pre-P and P subunits.  2  We therefore  propose that the recruitment of 
pre-P by the labile  C3/C5 convertase involves a nonenzymatic, conformational 
change of  the molecule. 
The fact  that pre-P does not  bind to  EC3b at  physiological  ionic  strength does 
not  rule  out  its  entering into  reversible  interaction  with C3b. That the molecule 
does possess affinity  for C3b could be shown by its adsorption to EC3b at 
unphysiologically low  ionic strength  (Table  If). When  aider washing  of 
EC3b,pre-P,  Factors B  and D  were added, stabilized  C5 convertase activity 
appeared.  However,  when  EC3b,pre-P  was  exposed  to physiological ionic 
strength, all of  the pre-P was released  from the cells  into  the fluid  phase. This 
reversible interaction  between pre-P and C3b is analogous to the behavior of 
other complement proteins which are designed to function in concert.  Thus, 
reversible complexes are formed by the following  proteins:  Clq, Clr, and Cls 
(17,  18),  C2 and C4 (19),  C5, C6, C7, C8, and C9 (20),  and Factor B and C3b (21, 
Fig. 11).  That at  low ionic  strength  pre-P is  present in  whole human serum as a 
complex, possibly  with native  C3, has  been reported  by Chapitis  and  Lepow (22). 
The functional  differences  between pre-P and P are considerable.  P appears  to 
aggregate on the surface of EC3b, as evidenced by the fact  that uptake of 
molecules may greatly exceed the number of  C3b molecules on EC3b (Fig.  7). 
Such unlimited binding does not occur with pre-P.  In the presence of  Factors B 
and D, pre-P binding approaches saturation  when one molecule is  bound per 30 
molecules of  C3b (Table I, Fig. 2). With regard to stabilization  of  the enzymes, 
the effect  of pre-P and P is quantitatively  identical  and independent of dose, 
provided the two properdin forms are reacted with EC3b in the presence of 
Factors  B and D (Fig.  8).  IfP  is  first  allowed to  attach  to  EC3b and  Factors  B and 
D are added subsequently, enzyme stabilization  is  variable  and dose dependent 
as also  reported  by Fearon and Austen (5).  The dose-related  increase  of  enzyme 
stabilization  may be due to the above mentioned aggregation of P on EC3b, 
which occurs  in  absence of  Factors  B and D but  not  in  their  presence.  The more P 
molecules are clustered  around on enzyme site,  the greater the stabilization. 
With Factors B and D in the reaction  mixture, P produced a given number of 
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stabilized C5 convertase sites which decayed with a half-life of 7 rain.  When the 
same amount of P  (same preparation) was added to EC3b before Factors B and 
D, fewer stabilized C5 convertase sites were produced, but these sites had a half- 
life of 18 min  (Fig.  8).  Whether  P  is a  physiological  form of properdin  or a 
laboratory artifact remains to be established.  It is conceivable that soluble 
arises through the action of  the C3bINA according to the following expression: 
EC3b,B +  pre-P---~EC3b,P,B 
EC3b,P,B--~EC3b,P  +  Bi 
EC3b,P  C3bINA )EC3bi  + 
The composition of the C3 and the C5 convertases differs in the number of C3b 
molecules. The C3 convertase in free solution (23) or bound to the surface of a 
cell (24) probably is composed of only one molecule of C3b and one molecule of 
activated  Factor  B.  In  contrast,  the  C5  convertase  requires  more  than  one 
molecule of C3b. The fact that C5 convertase activity could not be detected in 
free solution (2,  4,  25),  but appears under appropriate  conditions on particles, 
indicated that assembly of the enzyme requires a surface. As we have shown in 
this study, a  surface allows assembly of C5 convertase because it imposes the 
constraint upon two or more adjacent, surface bound C3b molecules to remain in 
a critical topographical relationship.  When C3b is randomly distributed on the 
surface of a cell, only C3 convertase activity appears after addition of Factors B 
and D. When C3b is distributed in clusters so as to provide a critical density of 
these molecules,  C3 and C5 convertase activity is generated upon addition of 
Factors B and D  (Fig. 6). Alternatively,  a  C3 convertase site can convert itself 
into  a  C5  convertase  site  by catalyzing  uptake  of additional  C3b molecules. 
These experiments show that the additional C3b molecule is as firmly attached 
to the cell membrane as the initial molecule and not as a terminal subunit to the 
C3b,B complex. A difference in subunit composition between the C3 and the C5 
convertase was previously inferred from kinetic studies by Brade et al.  (26). 
Examining more closely the data presented in Fig. 6, it becomes necessary to 
distinguish between the C3b multiplicity required for binding-activation of pre- 
P  and  that  required  for  expression  of stabilized  C5  convertase  activity.  For 
instance,  to achieve the equivalent of 0.42 Z  (Z  =  63%  lysis) of stabilized C3 
convertase activity, 3,000 focally distributed or 33,000 randomly distributed C3b 
molecules were needed.  At the level of 33,000 randomly distributed C3b mole- 
cules, the activity of the stabilized C5 convertase  (0.02 Z) measured only one- 
twentieth of that of the stabilized C3 convertase. Accordingly, we must assume 
that if binding-activation of pre-P requires two C3b molecules, expression of C5 
convertase  activity requires  at  least  three  C3b molecules.  This  conclusion  is 
further supported by the marked susceptibility to C3bINA action of the stabi- 
lized C5 convertase (C3--~--,~) and the relative resistance of the stabilized C3 
convertase  (C3-]~-B)  (Table  HI).  For  simplicity's  sake,  we  propose  to  omit 
reference to the C3b multiplicity required  for pre-P binding-activation  in the 
systematic denotations of the enzymes and to use the letter n  to refer to the 
greater  C3b  multiplicity  required  for  C5  convertase  activity  (C3bn,B  or 
C3b~,P,B) compared to the requirements  for C3 convertase activity (C3--~-~ or 
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The composition of the alternative pathway C3 and C5 convertases is thus 
very similar to that of  the classical convertases (27). C~  corresponds to C4-b-~,2, 
where C3b and C4b fulfill the function of  the acceptor and modulator of  Factor B 
and C2, respectively, and where the latter two entities carry the serine protease 
site (28). The additional C3b in C3b,,B and C3b molecule in C~ serve to 
confer C5 convertase function on the respective enzymes. 
How does properdin fulfill its stabilizing function? Properdin is an asymmetri- 
cal, string-like molecule composed of four presumably identical subunits  (10, 
29). Assuming a mol wt of 212,000 an s rate of 5.2S, and a ~ of 0.70, the f/fo may 
be calculated to be approximately 2.0. This value corresponds to an axial ratio of 
1:20. For reasons mentioned above, it is likely that one molecule of properdin 
enters in physical contact with at least two adjacent C3b molecules and one or 
two molecules of activated Factor B.  It is therefore not improbable that the 
string-like conformation of pre-P becomes rearranged upon binding-activation, 
such as to impose constraints on the lateral movement of the C3b molecules and 
on the dissociation of Factor B from the complex. 
Studying the effects of pre-P, it became apparent that it prolongs the half-life 
of the labile C3/C5 convertase only three-fourfold (Fig.  8). The more important 
biological function of properdin therefore may be its protection of C3b from the 
destructive action of the C3bINA (6). The C3b that is critical for C5 convertase 
activity is  relatively unprotected (Table  III).  The  C3b  in  the  stabilized  C3 
convertase, C3b,P~-B, is highly protected. The C3b in the complexes C3b,B and 
C3b,P is partially protected. Accordingly, the physiological function ofpre-P is a 
dual  one:  to  protect C3b  in  most  of its  complexes against  C3bINA  and  to 
diminish the entropy of the assembled C3/C5 convertase. 
To date, three modes of regulation are known for the enzymes of the pathway: 
spontaneous decay, destruction by C3bINA,  and  active disassembly by fllH. 
The protein ill, was observed in this laboratory in 1965 as a  protein without 
known function (9). Whaley and Ruddy (30) showed film to be the accelerator of 
C3bINA and, more importantly, to have a controlling function of its own. 
The main molecular events of the properdin pathway are summarized sche- 
matically in Fig. 12. Only those reactions are shown that proceed on or near the 
surface of an activating particle. The fluid phase side reactions and the regula- 
tory events have been omitted for the sake of clarity. The pathway comprises 
four essential components: initiating factor, Factors B,  D, and C3.  Properdin 
itself functions as an accessory component. Factor B represents the principal 
zymogen, being the catalytic subunit in the initial C3 convertase (~. IF,B,C3), 
the solid phase C3 convertase (S~. C3b,B), and in the C5 convertase (S~I"  C3--~,B). 
Factor D constitutes the second zymogen of the pathway. It participates in two 
reactions, the assembly of the initial C3 convertase and of the solid phase C3 
convertase. It has a dual function. It activates Factor B by enzymatic cleavage 
when it is in complex with C3b. And it activates Factor B in a nonenzymatic, 
reversible reaction when it is in complex with nephritic factor and C3 (4), or by 
implication with initiating factor and C3. Reversible activation of Factor B was 
first observed by Day and coworkers (31, 32). The protein C3 fulfills multiple 
functions. It acts in native form as modulator of Factor B  in the initial  C3 
convertase complex. As cell-bound C3b, it functions as anchor of the cell-bound 1090  ALTERNATIVE  PATHWAY  OF  COMPLEMENT 
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FIG.  12.  Schematic representation of the major molecular events of the properdin path- 
way.  For detailed explanation see text. 
C3 and C5 convertases. It also constitutes the acceptor and modulator of acti- 
vated Factor B within these enzymes. 
Aider the deposition of C3b on the surface of activating particles by the initial 
C3 convertase, the C3  and C5 convertases are assembled. The C5 convertase 
requires for its formation multiple surface bound C3b molecules in close physical 
proximity. In acting on C5 the enzyme initiates the self-assembly of the mem- 
brane attack complex, C5b-9. That the pathway is effective without properdin 
has also been demonstrated by the lysis of rabbit erythrocytes in properdin and 
C4-depleted serum (1). The enzyme is labile and is the target of regulators such 
as the C3bINA.  Properdin not only lends stability to the enzyme complex, but 
also provides some protection against the C3bINA.  Precursor properdin recog- 
nizes C3b and enters into reversible interaction with it. Binding and activation 
of pre-P occurs only when it collides with the surface-bound complex of at least 
two molecules of C3b and one molecule of activated Factor B. Thus, the assem- 
bly of the enzyme is a prerequisite for pre-P recruitment. This behavior is in 
contradistinction to that of P, which can bind directly to bound C3b and then 
engage in reverse assembly of the C3/C5 convertase. Although properdin fulfills 
a nonessential function in vitro, it appears probable to us that, because of its role 
as a potentiator of the alternative pathway, properdin deficiency in vivo might 
result in perturbation of natural resistance to infections. 
Summary 
In this study the physiological role of properdin and the differential subunit 
composition of the solid phase enzymes of the pathway have been explored. 
Cell-bound C3 and C5 convertase differ in their C3b requirement. Apparently 
one molecule of C3b is sufficient to allow formation of C3 convertase (C3b~-B), 
whereas two or more are required for generation of C5 convertase (C3b~,B). This 
conclusion was drawn from results indicating the critical role of the spacial 
distribution of C3b molecules on the cell surface in enzyme formation. 
While the  C3/C5 convertase is fully capable of acting on C5  and thereby R.  G.  MEDICUS,  O.  GOTZE,  AND  H.  J.  MULLER-EBERHARD  1091 
initiating the assembly of the cytolytic membrane attack complex, it is exceed- 
ingly labile  and  vulnerable to  destruction by the  C3b  inactivator.  It  is  the 
apparent role of  properdin to confer a degree of stability upon the labile enzyme 
and  to protect  its  C3  converta  function against enzymatic destruction.  To 
achieve  these  effects,  precursor  properdin  (pre-P)  is  recruited in  a  binding- 
activation reaction  by  the  labile  C3/C5  convertase.  Multiple  C3b  molecules 
appear to be needed for the formation of properdin-activating principle. 
Three modes of regulation have been described, which involve spontaneous 
dissociation enzymatic degradation by C3b inactivator and disassembly by fllN. 
The functional differences of pre-P and activated properdin (15) were deline- 
ated,  pre-P displaying a  weak affinity for C3b  and 15 the capacity of strong 
interaction, /~ generating a  soluble C3 convertase in serum and pre-P being 
unable to do so.  Because of the profound differences between native pre-P and 
the  laboratory product  P,  the  question  was  raised  as  to  whether soluble  15 
represents an unphysiological form of the protein. 
On the basis of  this and other studies, the conclusion was reached that in vitro 
properdin recruitment constitutes the terminal event of the properdin pathway, 
and that properdin augments the function of  C3/C5 convertase without changing 
its substrate specificity. 
Received for publication 10 June 1976. 
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